Residency · Residency · Urology

Non-Muscle-Invasive Bladder Cancer: Diagnosis and Staging

Overview

The diagnosis and staging of non-muscle-invasive bladder cancer (NMIBC) rely on several cystoscopic techniques, including white-light cystoscopy, blue-light cystoscopy, and narrow-band imaging, each offering distinct advantages in tumor visualization. The en-bloc resection technique is an emerging surgical approach that allows removal of the entire tumor in one piece, facilitating better pathological assessment. A critical factor in accurate staging is the presence of muscularis propria (detrusor muscle) in the resected specimen, which distinguishes NMIBC from muscle-invasive disease.

Epidemiology

Bladder cancer is the fourth most common cancer in men and occurs less frequently in women, with a male-to-female ratio of approximately 3:1. The median age at diagnosis is 73 years. About 75% of patients present with NMIBC. Cigarette smoking is the leading risk factor, increasing the risk by fourfold and accounting for roughly half of all cases. Occupational exposures to aromatic amines, commonly found in the dye, rubber, leather, and paint industries, also contribute to risk. Additional risk factors include prior cyclophosphamide chemotherapy, pelvic radiation, chronic bladder inflammation, and schistosomiasis, which is particularly associated with squamous cell carcinoma (SCC) of the bladder. In Western countries, over 90% of bladder cancers are urothelial carcinomas.

Presentation

The most common presenting symptom of bladder cancer is painless gross hematuria, occurring in about 80% of cases. Patients may also experience irritative voiding symptoms such as frequency, urgency, and dysuria, which can suggest the presence of carcinoma in situ (CIS). Occasionally, bladder cancer is discovered incidentally on imaging studies that reveal bladder wall thickening or an intraluminal mass. When microhematuria is detected, the standard workup includes cystoscopy combined with upper tract imaging, typically a CT urogram.

Diagnostic Workup

Cystoscopy

Cystoscopy remains the gold standard for detecting bladder tumors. Initial evaluation is often performed using office-based flexible cystoscopy to assess the number, size, location, and appearance of lesions. Papillary tumors typically have a frond-like, exophytic appearance and are usually lower grade. Sessile or solid tumors present as broad-based and infiltrative, raising concern for higher-grade disease. Flat erythematous lesions are suspicious for CIS.

Enhanced Cystoscopy

Blue-Light Cystoscopy (BLC) / Photodynamic Diagnosis (PDD)

Blue-light cystoscopy involves the intravesical instillation of hexaminolevulinate (Cysview) about one hour before the procedure. This agent is preferentially absorbed by neoplastic cells and fluoresces under blue-violet light, enhancing the detection of CIS by 25-30% compared to white-light cystoscopy alone. This technique reduces residual tumor rates and may improve recurrence-free survival. The American Urological Association (AUA) and Society of Urologic Oncology (SUO) guidelines recommend offering BLC when available, particularly during the initial transurethral resection of bladder tumor (TURBT) and when CIS is suspected.

Narrow-Band Imaging (NBI)

Narrow-band imaging uses optical filters to enhance visualization of mucosal microvasculature without requiring an intravesical agent. It improves detection of flat lesions, although the evidence supporting its superiority is less robust than that for BLC.

Urine Cytology

Urine cytology has high specificity (>90%) for detecting high-grade urothelial carcinoma and CIS but low sensitivity (~30%) for low-grade tumors. It is most useful for surveillance and CIS detection. The Paris System for Reporting Urinary Cytology standardizes interpretation into categories such as negative, atypical, suspicious for high-grade urothelial carcinoma, and positive for high-grade urothelial carcinoma.

Urine Biomarkers

Several urine-based biomarkers exist, including UroVysion fluorescence in situ hybridization (FISH), which detects chromosomal abnormalities involving chromosomes 3, 7, 17, and loss of 9p21. NMP22, a nuclear matrix protein, is FDA-approved but has limited specificity. Cxbladder is a gene expression panel. None of these biomarkers have replaced cystoscopy and cytology as the standard diagnostic tools but may complement them in selected clinical settings.

Upper Tract Imaging

CT urography is the standard imaging modality for evaluating hematuria and excluding upper tract urothelial carcinoma (UTUC). MRI urography serves as an alternative in patients with contrast allergies or renal insufficiency. Approximately 5% of bladder cancer patients have synchronous UTUC.

Transurethral Resection of Bladder Tumor (TURBT)

Goals

The primary goals of TURBT are to completely resect all visible tumor, obtain an adequate specimen for pathological staging—which must include muscularis propria—and provide both therapeutic and diagnostic benefits.

Technique

TURBT is performed under general or spinal anesthesia. A bimanual examination under anesthesia (EUA) is conducted before and after resection to assess tumor mobility and fixation. Using a resectoscope equipped with a monopolar or bipolar loop electrode, the surgeon resects the tumor in layers, starting with the exophytic component and then the base, including deep muscle. Specimens of the tumor and the deep base/muscle are collected separately and labeled for pathological evaluation. The resection base is cauterized after tumor removal. Any suspicious flat areas are resected, and random biopsies of normal-appearing mucosa may be taken if CIS is suspected.

Muscularis Propria in the Specimen

The presence of muscularis propria in the TURBT specimen is critical for accurate staging, as it allows differentiation between Ta/T1 tumors and muscle-invasive T2 disease. Absence of muscularis propria increases the risk of understaging. If muscularis propria is not identified, a repeat TURBT is mandatory within 2 to 6 weeks. It is important not to confuse the muscularis mucosae—a thin smooth muscle layer within the lamina propria—with the muscularis propria (detrusor muscle), as this distinction requires experienced pathological review and has significant staging implications.

En-Bloc Resection of Bladder Tumor (ERBT)

En-bloc resection involves removing the entire tumor as a single specimen, including the underlying muscle. Techniques include the use of HybridKnife, laser modalities such as thulium or holmium, or monopolar/bipolar loops. This approach offers advantages such as better specimen orientation, improved pathological staging, and a lower risk of obturator nerve reflex. ERBT is particularly suitable for tumors measuring 3 cm or less. Although not yet universally adopted, evidence supports comparable or improved staging accuracy and recurrence rates with this technique.

Obturator Reflex

Tumors located on the lateral bladder wall near the obturator nerve can trigger an electrical stimulation-induced thigh adduction known as the obturator reflex. This sudden movement poses a risk of bladder perforation during resection. Preventive measures include general anesthesia with muscle paralysis, bipolar resection, or an obturator nerve block.

Repeat TURBT (Re-TURBT)

A repeat TURBT is indicated within 2 to 6 weeks after the initial procedure for patients with T1 tumors, which carry a 33-55% risk of residual disease. It is also considered for high-grade Ta tumors, incomplete initial resections, or when muscularis propria is absent in the initial specimen. Re-TURBT upstages 25-50% of T1 tumors and, when combined with complete resection, reduces recurrence and progression rates. The AUA and National Comprehensive Cancer Network (NCCN) strongly recommend re-TURBT for all T1 tumors.

Pathologic Staging (TNM)

Bladder cancer staging follows the TNM system. Stage Ta tumors are papillary and confined to the urothelium without invasion of the lamina propria. Carcinoma in situ (CIS or Tis) is a flat, high-grade carcinoma confined to the urothelium. Stage T1 tumors invade the lamina propria (subepithelial connective tissue). T2a and T2b indicate invasion into the superficial (inner half) and deep (outer half) muscularis propria, respectively. Stage T3 involves invasion into perivesical tissue, and T4 denotes invasion into adjacent organs. Stages Ta, CIS, and T1 are classified as NMIBC, while T2 and above represent muscle-invasive bladder cancer (MIBC).

Grading (WHO 2004/2016)

Tumors are graded as low-grade or high-grade based on architectural patterns and cellular atypia. Low-grade tumors exhibit an orderly architecture with mild atypia, whereas high-grade tumors show disordered architecture with significant atypia, mitoses, and nuclear pleomorphism. All CIS lesions are high-grade by definition. Low-grade Ta tumors generally have a favorable prognosis with a low risk of progression, while high-grade T1 tumors carry a significant progression risk of 20-50% at five years.

Substaging of T1

T1 tumors can be further subclassified into T1a and T1b based on the depth of lamina propria invasion. T1a indicates invasion into the superficial lamina propria above the muscularis mucosae, while T1b involves invasion into the deep lamina propria at or below the muscularis mucosae. T1b and extensive T1 tumors have a worse prognosis. Although not yet officially incorporated into the TNM staging system, substaging is increasingly reported.

Variant Histology

Certain histologic variants such as micropapillary, nested, plasmacytoid, and sarcomatoid carcinomas are aggressive and may warrant early cystectomy even in the NMIBC setting. These variants should be reported by the pathologist as they significantly influence treatment decisions.

Risk Stratification (AUA/SUO)

Risk stratification guides treatment decisions. Low-risk NMIBC includes low-grade, solitary Ta tumors measuring 3 cm or less without prior recurrence. The recommended treatment is TURBT followed by a single immediate intravesical chemotherapy instillation. Intermediate-risk disease encompasses recurrent low-grade Ta tumors, multifocal low-grade Ta, low-grade Ta larger than 3 cm, and solitary high-grade Ta tumors measuring 3 cm or less. These patients typically receive TURBT followed by induction intravesical therapy with Bacillus Calmette-Guérin (BCG) or chemotherapy. High-risk disease includes high-grade T1 tumors, recurrent or multifocal high-grade Ta tumors larger than 3 cm, any CIS, and BCG failure. Treatment involves TURBT with re-TURBT, BCG induction, and maintenance therapy. Early cystectomy is considered for patients with the highest-risk features such as variant histology, lymphovascular invasion, or extensive T1 disease.

<image>A side-by-side comparison of white-light cystoscopy and blue-light cystoscopy (photodynamic diagnosis) of the same bladder, showing a papillary tumor visible under both modalities and a flat CIS lesion that is only visible (fluorescent) under blue light but appears normal under white light. Labeled annotations explain the enhanced detection of CIS with blue-light technology. Realistic cystoscopic image illustration style.</image>

<image>A cross-sectional diagram of the bladder wall showing histologic layers from lumen outward: urothelium, lamina propria (with muscularis mucosae), muscularis propria (detrusor muscle, inner and outer layers), and perivesical fat. Tumor stages Ta, CIS, T1, T2a, T2b, T3, and T4 are mapped to their corresponding depth of invasion with color-coded arrows. The distinction between muscularis mucosae and muscularis propria is clearly highlighted. Medical histology illustration style.</image>

<image>An infographic showing the AUA risk stratification for NMIBC (low, intermediate, high risk) with tumor characteristics for each category, recommended treatment approach (single instillation, induction chemotherapy/BCG, BCG with maintenance), and 5-year recurrence and progression rates. Each risk category is color-coded green, yellow, and red respectively. Clean clinical education infographic format.</image>

Clinical Pearls

The presence of muscularis propria (detrusor muscle) in the TURBT specimen is essential for accurate staging; its absence risks understaging and mandates a repeat TURBT. It is crucial to distinguish muscularis mucosae, a thin muscle layer within the lamina propria, from muscularis propria, as confusing these can lead to staging errors. Re-TURBT for T1 disease is one of the most impactful interventions in bladder cancer management, as it upstages 25-50% of patients and reduces recurrence when complete resection is achieved. Blue-light cystoscopy enhances CIS detection by 25-30% and should be utilized when available, especially during the initial TURBT. In older patients presenting with irritative voiding symptoms such as frequency, urgency, and dysuria without infection, suspicion for CIS should be raised, prompting random biopsies and cytology. Administering a single immediate post-TURBT intravesical chemotherapy instillation with agents like gemcitabine or mitomycin C within 24 hours reduces recurrence by approximately 35% in low-risk NMIBC and should not be omitted. Finally, performing a bimanual examination under anesthesia before and after TURBT provides valuable staging information, with fixation suggesting muscle-invasive or locally advanced disease.

References

• Babjuk M, et al. EAU Guidelines on Non-Muscle-Invasive Bladder Cancer. Eur Urol. 2022;81(1):75-94
• Chang SS, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol. 2016;196(4):1021-1029
• Burger M, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy. Eur Urol. 2013;63(1):131-137
• Sylvester RJ, et al. Systematic review and individual patient data meta-analysis of immediate postoperative intravesical chemotherapy. Eur Urol. 2016;69(2):231-244
• NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer, Version 3.2024

Read this lecture as Markdown